Rosemary Hemaya Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO, or IPI alone — Poster Session 1